Cat. No.: HY-B0217

Nitazoxanide

(Synonyms: NTZ; NSC 697855)

15 Cited Publications

고객리뷰

Based on 15 publication(s) in Google Scholar

Nitazoxanide (NTZ), an anthelmintic agent, exhibits a broad spectrum of activities against a wide variety of helminths, protozoa, and enteric bacteria infecting animals and humans. Nitazoxanide inhibits Giardia lamblia trophozoite proliferation in axenic culture with an IC₅₀ of 2.4 μM. Nitazoxanide can be used for the research of parasitic gastroenteritis. Nitazoxanide shows anti-Japanese encephalitis virus (JEV) activity in a mouse model.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.28%
CAS No.: 55981-09-4
화학식: C₁₂H₉N₃O₅S
분자량:307.28

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Nitazoxanide Chemical Structure

CAS No.: 55981-09-4

사이즈

가격

재고

수량

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability 견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

대량구매 문의

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (15)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Bioz

Biological Activity

제품 설명

Nitazoxanide (NTZ), an anthelmintic agent, exhibits a broad spectrum of activities against a wide variety of helminths, protozoa, and enteric bacteria infecting animals and humans. Nitazoxanide inhibits Giardia lamblia trophozoite proliferation in axenic culture with an IC₅₀ of 2.4 μM^[1]. Nitazoxanide can be used for the research of parasitic gastroenteritis. Nitazoxanide shows anti-Japanese encephalitis virus (JEV) activity in a mouse model^[2].

All Parasite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: NTZ	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
BHK-21	CC₅₀	25 μM Compound: 105	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Caco-2	IC₅₀	221 μM Compound: Nitazoxanide	Antiprolferative activity against human Caco2 cells assessed as inhibition of cell proliferation by measuring [3H]-thymidine incorporation incubated for 48 hrs by liquid scintillometry Antiprolferative activity against human Caco2 cells assessed as inhibition of cell proliferation by measuring [3H]-thymidine incorporation incubated for 48 hrs by liquid scintillometry	[PMID: 28601526]
Caco-2	IC₅₀	26.8 μM Compound: NTZ	Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human Caco-2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
HCT-116	IC₅₀	11.2 μM Compound: 28; NTZ	Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT colorimetric assay Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT colorimetric assay	[PMID: 38142509]
HCT-8	EC₅₀	>25 μM Compound: Nitazoxanide	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 29469575]
HCT-8	IC₅₀	3.25 μM Compound: Nitazoxanide, 1	Antiparasitic activity against Cryptosporidium parvum in HCT8 cells Antiparasitic activity against Cryptosporidium parvum in HCT8 cells	[PMID: 16480281]
HCT-8	IC₅₀	3.8 μM Compound: NTZ	Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells	[PMID: 18591280]
HEK-293T	CC₅₀	>40 μM Compound: Nitazoxanide	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HeLa	IC₅₀	35 μM Compound: NTZ	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
HeLa	IC₅₀	35 μM Compound: NTZ	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay	[PMID: 34055214]
HepG2	CC₅₀	>40 μM Compound: Nitazoxanide	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HepG2 2.2.15	CC₅₀	>100 μM Compound: 1, NTZ	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
HepG2 2.2.15	EC₅₀	0.12 μM Compound: 1, NTZ	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA measured 24 hrs after last dose Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA measured 24 hrs after last dose	[PMID: 21553812]
HepG2 2.2.15	EC₅₀	0.59 μM Compound: 1, NTZ	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA measured 24 hrs after last dose Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA measured 24 hrs after last dose	[PMID: 21553812]
HL-60	IC₅₀	20.1 μM Compound: NTZ	Antiproliferative activity against human HL60 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
HT-29	IC₅₀	>50 μM Compound: NTZ	Antiproliferative activity against human HT29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
Huh-7	CC₅₀	49 μM Compound: 1, NTZ, PH-5776	Cytotoxicity against human Huh7.5 cells after 3 days by neutral red dye assay Cytotoxicity against human Huh7.5 cells after 3 days by neutral red dye assay	[PMID: 22059983]
PC-3	IC₅₀	44.7 μM Compound: NTZ	Antiproliferative activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34055214]
Peritoneal macrophage	IC₅₀	2 mM Compound: 36, NTZ	Anti-inflammatory activity against mouse peritoneal macrophages assessed as reduction in LPS induced IL-6 level by ELISA analysis Anti-inflammatory activity against mouse peritoneal macrophages assessed as reduction in LPS induced IL-6 level by ELISA analysis	[PMID: 32992245]
RAW264.7	IC₅₀	1.54 mM Compound: 36, NTZ	Anti-inflammatory activity against mouse RAW264.7 cells assessed as reduction in LPS induced IL-6 level by ELISA analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as reduction in LPS induced IL-6 level by ELISA analysis	[PMID: 32992245]
U2OS	CC₅₀	25 μM Compound: 105	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Vero	CC₅₀	833 μM Compound: NIT, Alinia	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 21397502]
Vero	CC₅₀	833 μM Compound: Nitazoxanide	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 25801157]
Vero	CC₅₀	833 μM Compound: Nitazoxanide	Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay	[PMID: 28645659]
Vero	CC₅₀	833 μM Compound: NTZ	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 24529307]
Vero	IC₅₀	10.74 μM Compound: NTZ	Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by WST-1 assay Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 23787289]
Vero C1008	CC₅₀	>35.5 μM Compound: 48	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]

In Vitro

Giardia lamblia, a flagellated protozoan, is the most common causative agent of persistent diarrhea worldwide^[1].
Nitazoxanide exhibits effect on G. lamblia trophozoite proliferation in axenic culture with an IC₅₀ of 2.4 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human cancer colon Caco2 cells were incubated with increasing numbers of Giardia lamblia trophozoites (10³ to 10⁶ parasites per well)
Concentration:

30 μM
Incubation Time:

24 hours
Result:

70 to 90% of the trophozoites remained attached to the Caco2 cells for a period of 24 to 48 h in the absence of Nitazoxanide and at an initial inoculum density of 10⁵ parasites per well.
The number of parasites still attached to Caco2 cells after 24 h decreased to less than 20% of the control value in the presence of 30 μM Nitazoxanide with an inoculum density of 10⁵ trophozoites.

In Vivo

Nitazoxanide exhibits a wide spectrum of in vivo activity against a broad spectrum of intestinal parasites, such as Giardia lamblia, Entamoeba histolytica, Trichomonas vaginalis, the apicomplexan Cryptosporidium parvum, and enteric bacteria infecting animals and humans^[1].
Nitazoxanide (50, 75 or 100 mg/kg/day; administered daily by intragastric for up to 25 days) reduces the mortality of Japanese encephalitis virus (JEV) strain-infected mice and protected mice from a lethal dose challenge of JEV^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Three-week old female Chinese Kunming mice (12–14 g body weight) were infected intraperitoneally with JEV^[2]
Dosage:

50, 75 or 100 mg/kg/day
Administration:

Administered intragastrically by gavage
Result:

50 mg/kg/day, 75 mg/kg/day and 100 mg/kg/day led to 30%, 70% and 90% mice survival, respectively.

Chemical Information

CAS No. 55981-09-4
Appearance Solid
분자량 307.28
화학식 C₁₂H₉N₃O₅S
Color Light yellow to yellow
SMILES

O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=CC=C2OC(C)=O
Synonyms

NTZ; NSC 697855
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All IFELISAWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Autophagy

Trans-Golgi network-associated noncanonical autophagy depends on the V-ATPase-ATG16L1 axis and mediates IL1B secretion. [Abstract]

2025 Dec 8. PMID: 41361996

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 8. [Abstract]

Nitazoxanide (NTZ) (10 μM; 6 h) could induce significant colocalization of LC3 and TGOLN2 in RB1CC1^−/−-HeLa cells.

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 8. [Abstract]

ELISA analysis of IL1B in culture medium supernatant of wt THP-1 cells, RB1CC1 KD-THP-1 cells or ATG16L1^−/−-THP-1 cells treated with LPS (1 μg/mL, 2 h), followed by treatment with nigericin (NIG, 10 μM), AMDE-1 (10 μM), HCP (20 μM), SFG (20 μM), and Nitazoxanide (NTZ) (20 μM) for 4 h.

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 8. [Abstract]

Immunoblot analysis of LC3 in rb1cc1^−/−-MEF cells treated with 10 μM of AMDE-1, HCP, SFG, and Nitazoxanide (NTZ) with or without brefeldin a (BFA, 20 μM) or golgicide a (GCA, 20 μM) for 6 h.

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Dec 8. [Abstract]

Transmission electron microscopy analysis of rb1cc1^−/−-MEF cells treated with 10 μM of AMDE-1, HCP, SFG, and Nitazoxanide (NTZ) for 1 h and 6 h. Scale bar: 500 nm.
Cell Rep Med

Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. [Abstract]

2024 Dec 30:101890. PMID: 39793570
Pharmacol Res

Time-dependent proteomics and drug response in expanding cancer cells. [Abstract]

2024 May 9:204:107208. PMID: 38729587
Cell Death Dis

Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma. [Abstract]

2018 Oct 9;9(10):1032. PMID: 30302016

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 9;9(10):1032. [Abstract]

Western blot showing the cell cycle and autophagy-related proteins after 48 h of treatment with 200 μM Nitazoxanide (NTZ) and/or 500 nM Torin 1 or 30 mM Chloroquine (CQ).

Nitazoxanide purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Oct 9;9(10):1032. [Abstract]

Western blot showing SQSTM1 and LC3 levels in LN229 cells after treatment with 200 μM Nitazoxanide (NTZ) and 200 nM Bafilomycin A1 (BAF) for 48 h.
BMC Med

Nitazoxanide inhibits acetylated KLF5-induced bone metastasis by modulating KLF5 function in prostate cancer. [Abstract]

2023 Feb 21;21(1):68. PMID: 36810084
ACS Environ Au

Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]

2025 Aug 5;5(6):573-582. PMID: 41277996
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Biochem Pharmacol

Nitazoxanide impairs mitophagy flux through ROS-mediated mitophagy initiation and lysosomal dysfunction in bladder cancer. [Abstract]

2021 Aug:190:114588. PMID: 33957094
Chem Biol Interact

Anti-cancer effects of nitazoxanide in epithelial ovarian cancer in-vitro and in-vivo. [Abstract]

2024 Jul 30:400:111176. PMID: 39084502
Biomolecules

Repurposing Nitazoxanide for Potential Treatment of Rare Disease Lymphangioleiomyomatosis. [Abstract]

2024 Sep 30;14(10):1236. PMID: 39456169
mBio

Regulation of the WNT-CTNNB1 signaling pathway by severe fever with thrombocytopenia syndrome virus in a cap-snatching manner. [Abstract]

2023 Dec 19;14(6):e0168823. PMID: 37882780
Antimicrob Agents Chemother

Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. [Abstract]

2021 Mar 18;65(4):e01445-20. PMID: 33495223
iScience

ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis. [Abstract]

2024 Mar 19;27(4):109533. PMID: 38591006
Microbiol Spectr

Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo. [Abstract]

2024 Jan 11;12(1):e0229523. PMID: 38032179
Universidade de São Paulo

2020 Sep.

용액&용해도

In Vitro:

DMSO : ≥ 100 mg/mL (325.44 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2544 mL

16.2718 mL

32.5436 mL

5 mM

0.6509 mL

3.2544 mL

6.5087 mL

10 mM

0.3254 mL

1.6272 mL

3.2544 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.25 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Rossignol JF, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009 Oct 23;284(43):29798-808. [Content Brief]

[2]. Zixue Shi, et al. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J. 2014 Jan 23;11:10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2544 mL	16.2718 mL	32.5436 mL	81.3590 mL
	5 mM	0.6509 mL	3.2544 mL	6.5087 mL	16.2718 mL
	10 mM	0.3254 mL	1.6272 mL	3.2544 mL	8.1359 mL
	15 mM	0.2170 mL	1.0848 mL	2.1696 mL	5.4239 mL
	20 mM	0.1627 mL	0.8136 mL	1.6272 mL	4.0680 mL
	25 mM	0.1302 mL	0.6509 mL	1.3017 mL	3.2544 mL
	30 mM	0.1085 mL	0.5424 mL	1.0848 mL	2.7120 mL
	40 mM	0.0814 mL	0.4068 mL	0.8136 mL	2.0340 mL
	50 mM	0.0651 mL	0.3254 mL	0.6509 mL	1.6272 mL
	60 mM	0.0542 mL	0.2712 mL	0.5424 mL	1.3560 mL
	80 mM	0.0407 mL	0.2034 mL	0.4068 mL	1.0170 mL
	100 mM	0.0325 mL	0.1627 mL	0.3254 mL	0.8136 mL

Nitazoxanide

15 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Nitazoxanide

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nitazoxanide

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (15)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Nitazoxanide

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nitazoxanide

All Parasite Isoforms

Biological Activity

Chemical Information

Publications (15)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Nitazoxanide Related Classifications

Cat. No.: HY-B0217